Morgan Stanley started coverage on shares of Genmab A/S (NASDAQ:GMAB) in a research note released on Monday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rating on the stock.
Shares of Genmab A/S stock opened at $19.89 on Monday. Genmab A/S has a 1 year low of $12.10 and a 1 year high of $21.45.
A hedge fund recently bought a new stake in Genmab A/S stock. Parametric Portfolio Associates LLC purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 375,476 shares of the company’s stock, valued at approximately $6,937,000. Parametric Portfolio Associates LLC owned 0.29% of Genmab A/S as of its most recent filing with the Securities & Exchange Commission. 0.80% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
See Also: Momentum Indicators
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.